Protein kinase D is implicated in the reversible commitment to differentiation in primary cultures of mouse keratinocytes.
Although commitment to epidermal differentiation is generally considered to be irreversible, differentiated keratinocytes (KCs) have been shown to maintain a regenerative potential and to reform skin epithelia when placed in a suitable environment. To obtain insights into the mechanism of reinitiation of this proliferative response in differentiated KCs, we examined the reversibility of commitment to Ca(2+)-induced differentiation. Lowering Ca(2+) concentration to micromolar levels triggered culture-wide morphological and biochemical changes, as indicated by derepression of cyclin D1, reinitiation of DNA synthesis, and acquisition of basal cell-like characteristics. These responses were inhibited by Goedecke 6976, an inhibitor of protein kinase D (PKD) and PKCalpha, but not with GF109203X, a general inhibitor of PKCs, suggesting PKD activation by a PKC-independent mechanism. PKD activation followed complex kinetics with a biphasic early transient phosphorylation within the first 6 h, followed by a sustained and progressive phosphorylation beginning at 24 h. The second phase of PKD activation was followed by prolonged ERK1/2 signaling and progression to DNA synthesis in response to the low Ca(2+) switch. Specific knockdown of PKD-1 by RNA interference or expression of a dominant negative form of PKD-1 did not have a significant effect on normal KC proliferation and differentiation but did inhibit Ca(2+)-mediated reinitiation of proliferation and reversion in differentiated cultures. The present study identifies PKD as a major regulator of a proliferative response in differentiated KCs, probably through sustained activation of the ERK-MAPK pathway, and provides new insights into the process of epidermal regeneration and wound healing.
Jadali
Azadeh
A
Graduate Program in Molecular and Cellular Biology, Stony Brook University, Stony Brook, New York 11794, USA.
Ghazizadeh
Soosan
S
D000818:Animals; D002118:Calcium / Q000378:metabolism / Q000494:pharmacology; D002227:Carbazoles / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D000078404:Epidermal Cells; D004817:Epidermis / Q000187:drug effects / Q000201:enzymology; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D015603:Keratinocytes / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology*; D007700:Kinetics; D020935:MAP Kinase Signaling System / Q000187:drug effects; D051379:Mice; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*
D002227:Carbazoles; C081021:Go 6976; C089212:protein kinase D; D011493:Protein Kinase C; D002118:Calcium
J Biol Chem. 2000 Jun 16;275(24):18476-81
10764790
Crit Rev Oral Biol Med. 1999;10(4):442-57
10634582
PLoS Biol. 2006 Mar;4(3):e83
16509772
Endocr Rev. 2009 Apr;30(2):178-95
19237714
Mech Dev. 1995 Apr;50(2-3):139-50
7619726
J Biol Chem. 2005 Apr 8;280(14):13205-8
15701647
Trends Pharmacol Sci. 2006 Jun;27(6):317-23
16678913
BMC Dev Biol. 2008 Apr 25;8:47
18439271
Nat Rev Cancer. 2003 Jun;3(6):444-51
12778134
J Invest Dermatol. 2010 Feb;130(2):388-97
19675579
Oncogene. 1996 Jul 4;13(1):167-76
8700543
J Invest Dermatol. 2005 Aug;125(2):294-306
16098040
Mol Cell Endocrinol. 2003 Feb 28;200(1-2):189-98
12644311
Drug News Perspect. 2004 Mar;17(2):117-26
15098066
Cell. 2001 Feb 23;104(4):605-17
11239416
J Invest Dermatol. 1983 Jul;81(1 Suppl):100s-3s
6345687
Cancer Res. 2000 Aug 1;60(15):4085-92
10945614
J Biol Chem. 1998 Jul 17;273(29):18623-32
9660836
Cancer Res. 1982 Jun;42(6):2344-9
6122503
Cell. 1980 Jan;19(1):245-54
6153576
Cancer Res. 2006 Mar 1;66(5):2700-7
16510590
J Invest Dermatol. 2002 Nov;119(5):1128-36
12445203
J Invest Dermatol. 2009 Oct;129(10):2365-75
19340015
Exp Dermatol. 2005 Oct;14(10):727-35
16176280
J Cell Biochem. 2009 Mar 1;106(4):714-28
19173301
J Biol Chem. 2008 Feb 8;283(6):3519-3528
18065418
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9089-94
10430900
Cell. 1999 Jul 9;98(1):59-68
10412981
Cancer Cell. 2002 Sep;2(3):243-7
12242156
Trends Biochem Sci. 1995 May;20(5):187-90
7610482
J Biol Chem. 2004 Jan 2;279(1):259-64
14573624
J Biol Chem. 2003 Jan 3;278(1):154-63
12407104
J Biol Chem. 2008 May 9;283(19):12877-87
18337243
J Invest Dermatol. 1999 Dec;113(6):1099-105
10594758
J Biol Chem. 2004 Apr 16;279(16):16883-93
14963034
Dev Cell. 2007 Apr;12(4):615-29
17419998
Biol Cell. 2005 Mar;97(3):173-83
15715523
Cell. 2004 Sep 3;118(5):635-48
15339667
Cell. 1995 Jan 27;80(2):179-85
7834738
J Cell Biol. 2002 Jan 7;156(1):65-74
11777941
J Biol Chem. 2003 May 16;278(20):17969-76
12637538
Cell. 1995 Dec 15;83(6):957-68
8521519
J Invest Dermatol. 2005 May;124(5):1014-25
15854044
Mol Cell Biol. 1990 Aug;10(8):4239-42
2370865
Bioessays. 2000 Sep;22(9):818-26
10944584
J Biol Chem. 2009 May 15;284(20):13434-13445
19289471
Curr Opin Cell Biol. 1990 Dec;2(6):1028-35
1712211
J Biol Chem. 1999 Apr 2;274(14):9224-30
10092595
EMBO J. 1996 Nov 15;15(22):6220-30
8947045
Carcinogenesis. 2000 May;21(5):1031-7
10783329
Science. 1997 Apr 4;276(5309):75-81
9082989
J Invest Dermatol. 1987 Sep;89(3):253-63
2442269
Int J Cancer. 1999 Jan 5;80(1):98-103
9935238
J Cell Biol. 2007 Mar 12;176(6):807-18
17353358
J Cell Biol. 1989 Sep;109(3):1207-17
2475508
FEBS Lett. 2003 Jul 3;546(1):81-6
12829240
Am J Physiol Renal Physiol. 2001 Feb;280(2):F291-302
11208605